190 related articles for article (PubMed ID: 36958399)
1. Targeting intracellular and extracellular receptors with nano-to-macroscale biomaterials to activate immune cells.
Wang B; Cui H; Kiessling F; Lammers T; Baumjohann D; Shi Y
J Control Release; 2023 May; 357():52-66. PubMed ID: 36958399
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy.
Dong Q; Xue T; Yan H; Liu F; Liu R; Zhang K; Chong Y; Du J; Zhang H
J Nanobiotechnology; 2023 Oct; 21(1):395. PubMed ID: 37899463
[TBL] [Abstract][Full Text] [Related]
3. Advances in immunotherapy delivery from implantable and injectable biomaterials.
Leach DG; Young S; Hartgerink JD
Acta Biomater; 2019 Apr; 88():15-31. PubMed ID: 30771535
[TBL] [Abstract][Full Text] [Related]
4. Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy.
Lee D; Huntoon K; Wang Y; Jiang W; Kim BYS
Adv Mater; 2021 Jul; 33(27):e2007576. PubMed ID: 34050699
[TBL] [Abstract][Full Text] [Related]
5. Surgery-free injectable macroscale biomaterials for local cancer immunotherapy.
Lei K; Tang L
Biomater Sci; 2019 Feb; 7(3):733-749. PubMed ID: 30637428
[TBL] [Abstract][Full Text] [Related]
6. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
7. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
8. Role of dendritic cells in the host response to biomaterials and their signaling pathways.
Zhu FJ; Tong YL; Sheng ZY; Yao YM
Acta Biomater; 2019 Aug; 94():132-144. PubMed ID: 31108257
[TBL] [Abstract][Full Text] [Related]
9. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy.
Huang P; Wang X; Liang X; Yang J; Zhang C; Kong D; Wang W
Acta Biomater; 2019 Feb; 85():1-26. PubMed ID: 30579043
[TBL] [Abstract][Full Text] [Related]
10. Biomaterials as Local Niches for Immunomodulation.
Adu-Berchie K; Mooney DJ
Acc Chem Res; 2020 Sep; 53(9):1749-1760. PubMed ID: 32786230
[TBL] [Abstract][Full Text] [Related]
11. Immunologically active biomaterials for cancer therapy.
Ali OA; Mooney DJ
Curr Top Microbiol Immunol; 2011; 344():279-97. PubMed ID: 20556594
[TBL] [Abstract][Full Text] [Related]
12. Emerging nanomedicines for effective breast cancer immunotherapy.
Bahreyni A; Mohamud Y; Luo H
J Nanobiotechnology; 2020 Dec; 18(1):180. PubMed ID: 33298099
[TBL] [Abstract][Full Text] [Related]
13. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.
Lynn GM; Laga R; Jewell CM
Cancer Lett; 2019 Sep; 459():192-203. PubMed ID: 31185250
[TBL] [Abstract][Full Text] [Related]
14. Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy.
Seo HS; Wang CJ; Park W; Park CG
Tissue Eng Regen Med; 2022 Apr; 19(2):263-280. PubMed ID: 34596839
[TBL] [Abstract][Full Text] [Related]
15. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
Front Immunol; 2020; 11():599083. PubMed ID: 33281825
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
17. Biomaterials in treatment of Alzheimer's disease.
Agrawal M; Prathyusha E; Ahmed H; Dubey SK; Kesharwani P; Singhvi G; Naidu VGM; Alexander A
Neurochem Int; 2021 May; 145():105008. PubMed ID: 33684545
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Selective Activation of Toll-Like Receptor 7/8 Agonist Nano-Immunomodulator Generates Safe Anti-Tumor Immune Responses upon Systemic Administration.
Hao Y; Li H; Ge X; Liu Y; Li X; Liu Y; Chen H; Zhang S; Zou J; Huang L; Zhao F; Kang D; De Geest BG; Zhang Z
Angew Chem Int Ed Engl; 2022 Dec; 61(52):e202214992. PubMed ID: 36331428
[TBL] [Abstract][Full Text] [Related]
19. Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.
de Brito CA; Goldoni AL; Sato MN
Immunotherapy; 2009 Sep; 1(5):883-95. PubMed ID: 20636030
[TBL] [Abstract][Full Text] [Related]
20. Boosting Checkpoint Immunotherapy with Biomaterials.
Liu L; Pan Y; Zhao C; Huang P; Chen X; Rao L
ACS Nano; 2023 Feb; 17(4):3225-3258. PubMed ID: 36746639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
